

FOSUN PHARMA
复星医药

2023



- ①
- ②
- ③
- ④
- ⑤
- ⑥



1H23

1/2

▪
▪
▪

▪
▪
▪
▪

▪
▪
▪

▪
▪

▪
▪
▪
▪

1H23

2/2

1H23	1H22			1H23	2022
213.95	213.48	{			
106.97	97.7			148.85	162.41
50.0%	45.8%	{			
50.71	41.75			454.60	445.82
23.7%	19.6%	{			
26.3%	26.2%			1.00	1.06
20.45	16.79	{			
9.6%	7.9%			0.79	0.85
21.34	18.27	{			
10.0%	8.6%			50.6%	49.5%
5.45	2.62	{			
2.5%	1.2%				

Sisram

PD-1



® PD-1

1H23 5.56

3 ES-SCLC

PD-1

3 ES-SCLC

ES-SCLC

MAA


EMA




2/2








&







2023 - 2024



2019 - 2022




Gland



API





MSCI-ESG

A

A

2023

BBB
2021

BB
2020

2023

MSCI ESG
*

A

2023

ESG

A-

A

A



E nvironment

EHS

2021-2026

EHS

EHS

2022

115.36

337,806

3.2%



S ocial

PQ

Argesun®

3

WHO

1



G overnance

ESG


ESG

10


2023 1




1



2,3



3



SCLC

PD-1












1H23

5.56



(ASTCT)										r/r LBCL									
2023 6 r/r LBCL																			
CAR-T																			
B																			
LBCL																			
LBCL NHL 45.8%																			
1.3																			
NHL																			
LBCL 4																			
</																			










-

1

1,2

1







8.99%

1
2




2023









1



2,3



3



2011-2017



2018-2020



2021



600

2017 11

9.09

1,750




2022

21.45

1.11

87.41%









		®		
		®		
		®		
		®		
		®		

		®		
		®		
		®		
		®		
		®		
		®		

		⑧		
		⑧		
				
		⑧		
		⑧		
				

1/2

			/			IND	1	2	3	NDA
HLX10 ¹	+		PD-1	/	III 2022 11					
					2022 11 2022 FDA/EC 2023 1					
	+ +		PD-1		III 2023 1 2022 5					
	+		PD-1+VEGF							
	+HLX07		PD-1+EGFR							
	+HLX07 +		PD-1+EGFR +VEGF		2022 1					
	HLX07		EGFR							
	HLX22									
HLX11		2	HER2	III 2022						
HLX05		3	EGFR							
HLX02		4	HER2	FDA 2020						

1 KG Bio 10
3
5 2023 7 31

2 Organon
4 Accord Cipla Jacobson mAbxience Eurofarma Abbott



2/2

[illegible]

1/2

		I		IND	1	2	3	NDA
FCN-437c		CDK4/6	1L					
			2L					
SAF-189		ALK/ROS1	ALK+					
			ROS1+					
HLX-208	-	BRAF	Erdheim-Chester ECD LCH					
		BRAF+PD-1	BRAF V600E BRAF V600					
FCN-159		MEK	I					
YP01001		VEGFR						
FCN-338		BCL-2						

2/2

		/			IND	1	2	3	NDA
		TPO-R	ITP						
	Tenapanor	NHE 3	(ESRD-HD)						
		P-CAB							
	Tenapanor	NHE 3	(IBS-C)						
	PA-824	-	XDR-TB / MDR-TB						
	Opicapone	COMT							
	Fortacin								

			IND	1	2	3	NDA
	/						
	/						
	/						
13							
24							
23							
	-						

FOSUN □

LOGO

Fosun Pharma, the Representor or the Provider will not warrant the accuracy, the completeness and the timeliness of all information and contents, including predictive description, contained in the PPT documents/visual materials. In the event of any mistake, omission, and inaccuracy, Fosun Pharma, the Representor or the Provider should not be held for any liabilities in this regard.

The PPT documents/visual materials will not include and should not be deemed as any investment proposals. The investor should take their own responsibilities for any determinations so come to based upon the information contained in the PPT documents/visual materials.

Fosun Pharma is entitled to all rights, including copyright, pertaining to the PPT documents/visual materials. The characters, the designs and other related logos, like Fosun □ and , are the trade name, trademark and the logos legally owned by Fosun Pharma. Without written consent offered by Fosun Pharma, any third party should not utilize such materials and information in any manner, including reprinting.



www.fosunpharma.com